By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted August 11, 2022APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOK READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted July 27, 2022APYX MEDICAL CORPORATION RELEASES ENVIRONMENTAL, SOCIAL AND GOVERNANCE DATA IN NEW TEAR SHEET READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted July 18, 2022RENUVION CLEARED BY FDA FOR NECK LAXITY PROCEDURES OFFERING PATIENTS A MINIMALLY INVASIVE OPTION TO ELIMINATE SAGGING NECK READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted July 18, 2022APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO IMPROVE APPEARANCE OF LAX (LOOSE) SKIN READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted July 8, 2022APYX MEDICAL CORPORATION ANNOUNCES RESULTS OF THE U.S. IDE CLINICAL STUDY EVALUATING THE USE OF RENUVION TO IMPROVE THE APPEARANCE OF LAX SKIN IN THE NECK AND SUBMENTAL REGION READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted June 30, 2022APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2022 FINANCIAL RESULTS ON AUGUST 11, 2022 READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted June 28, 2022RENUVION DERMAL HANDPIECE FOR WRINKLE-REDUCTION PROCEDURES CLEARED BY FDA READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted May 26, 2022APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION COSMETIC TECHNOLOGY IN DERMAL RESURFACING PROCEDURES READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted May 25, 2022APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN JUNE READ MORE
By apyxmedical In 2022 Shareholder News, J-Plasma, RenuvionPosted May 12, 2022APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND UPDATES FULL YEAR 2022 FINANCIAL OUTLOOK READ MORE
